Pulsed Dye Laser (PDL) vs. Microsecond 1064-nm Nd:YAG Laser for Treatment of Diffuse Facial Redness

Comparison of the Efficacy Between Pulsed Dye Laser (PDL) and the Microsecond 1064-nm Nd:YAG Laser for Treatment of Diffuse Facial Redness: A Pilot, Prospective Randomized Trial.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01529996

Enrollment

Registered

2012-02-09

Start date

2012-01-31

Completion date

2012-08-31

Last updated

2021-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Brief summary

The primary objective of this study is to compare the efficacy of PDL and the 1064-nm Nd:YAG laser in the treatment of facial redness.

Interventions

PROCEDUREPulse Dye Laser/YAG laser

This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy patients 18-55 years of age with erythematotelangiectatic rosacea (as verified by the the PI). * Subjects who are willing to provide informed consent for participation in the study.

Exclusion criteria

* Pregnant or lactating individuals * Subjects who are unable to understand the protocol or to give informed consent. * Subjects who have a known history of photosensitive conditions (e.g. Systemic lupus, polymorphous light eruption) * Subjects who have facial telangiectasia of diameter greater than 2 mm. * Subject who have significant (as determined by the PI) acute inflammatory papules, pustules, and vesicle involving the central face.

Design outcomes

Primary

Measure	Time frame	Description
Rating on global improvement scale	four months	Non-treating dermatologists will rate each side of the face using a global improvement scale to evaluate the effectiveness of the two treatments.
Spectrophotometer measurement	four months	Spectrophotometer measurement as the percent resolution on each follow up visit compared to baseline visit

Secondary

Measure	Time frame	Description
Patient satisfaction	four months	Patients will record satisfaction on the questionnaires provided
Recorded discomfort	four months	Subjects will record discomfort using a 10-point scale
Adverse events	four months	Any adverse events will be recorded

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026